The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).
 
Vivek Narayan
Honoraria - Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Exelixis; Janssen Oncology; Merck; Myovant Sciences; Pfizer/EMD Serono; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Tmunity Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Alexandra Torres
No Relationships to Disclose
 
Philip Seger
No Relationships to Disclose
 
Megan Aaron
No Relationships to Disclose
 
Jennifer Louie
No Relationships to Disclose
 
Daniel Lee
No Relationships to Disclose
 
Naomi B. Haas
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Expert Testimony - Lilly (I)
 
Samuel U Takvorian
Stock and Other Ownership Interests - Bluebird Bio (I); Gilead Sciences (I); Johnson & Johnson (I); Merck (I); Novartis (I); Pfizer (I); Pfizer (I); Portola Pharmaceuticals (I)
Consulting or Advisory Role - AstraZeneca/Merck; Boehringer Ingelheim (I); Genentech; Health Advances; Novartis (I); Novocure (I)
Research Funding - AstraZeneca (I); Lilly (I); Pfizer; Trizell (I)
 
Kara Noelle Maxwell
No Relationships to Disclose
 
Susan M. Domchek
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)